Teva, Lilly and Amgen join battle for new $8bn migraine prevention market
This article was originally published in Scrip
Executive Summary
New biologicals targeting the CGRP pathway could prove to be the biggest thing to hit the migraine market since the triptans in the 1990s, mid-stage data presented at the recent American Headache Society meeting in Washington suggest.